Transcutaneous Auricular Vagus Nerve Stimulation Device in CKD Population
Start Date
8/9/2023
Completion Date
1/7/2026
Summary
The purpose of this pilot interventional study is to collect preliminary data on the application of a transcutaneous auricular vagal nerve stimulation (taVNS) device in patients with chronic kidney disease (CKD). This data will enhance understanding of the short-term safety, tolerability and effects of this novel therapeutic approach in the setting of CKD. The primary aims are to investigate the feasibility of the protocol and generate preliminary signals of efficacy and tolerability for two different doses of vagal nerve stimulation. The pilot estimates will be used to design a larger scale study that may lead to potentially targeted interventions to reduce cardiovascular (CV) mortality in the CKD population.
Eligibility Criteria
Age Range: 18 years to 80 years
Interventions
Transcutaneous electrical nerve stimulation unit (TENS)
Conditions
Locations
NYU Langone Health
New York, New York 11215
United States